Jonathon Cohen, MD
Enriched profileProfessor, Department of Hematology and Medical Oncology, Emory University School of Medicine · Winship Cancer Institute
Jonathon Cohen is Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine at Winship Cancer Institute. OpenAlex indexes 448 publications with 9,203 citations (h-index 44); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jonathon Cohen, M.D., is Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine at Winship Cancer Institute, Emory University School of Medicine. The public record shows 448 publications with 9,203 citations (h-index 44), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 16 companies, 1 NIH-funded awards (2023–2025).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Lymphoma Diagnosis and Treatment
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 44 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 127.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Sponsor: National Cancer Institute (NCI)
- A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Sponsor: Eli Lilly and Company
Industry payments
Updated 27 Aug 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- National Marrow Donor ProgramProgram year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Incyte CorporationProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.5%Kinase inhibitor40.2%Brukinsa78%Imbruvica11%Calquence11%Part D<11 patientsBCL-2 Inhibitor15.3%Venclexta100%Part D≥13 patientsAnti-infectives
31.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.4%Valacyclovir100%Part D≥37 patientsShort-acting sulfonamides5.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsDermatology
5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor5%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute
Emory University
FY2025$156,603R50CA276010 - Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute
Emory University
FY2024$156,603R50CA276010 - Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute
Emory University
FY2023$156,603R50CA276010
Congress activity
Updated 27 Aug 2026
169 congress contributions (2015–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma
ASH Annual Meeting
ASH2025Co-author - FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Blood advances
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyArticle465 citations2021
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jonathon-cohen-md-de26
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
bloodcancerunited.org/award-recipient/jonathon-cohen
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗ - X / Twitter
X/Twitter: @jonathonbcohen
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emoryhealthcare.org ↗
- M.S. in Medical Science
The Ohio State University (completed during hematology/oncology fellowship)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emoryhealthcare.org ↗
Editorial & leadership roles
journal and society appointments- Co-Director
Lymphoma Program, Winship Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Chair
State of Science Summit -- Leukemia/Lymphoma (OncLive)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Member
ECOG-ACRIN Lymphoma Core Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗
Media & interviews
press, podcasts and appearances- Recurring OncLive contributor -- video interviews on mantle cell lymphoma
follicular lymphoma, and CAR T-cell therapy management
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerstoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center